查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2144448

醫療植入和組織工程生物材料市場預測至2034年—按材料類型、功能、應用、最終用戶和地區分類的全球分析

Biomaterials for Medical Implants & Tissue Engineering Market Forecasts to 2034 - Global Analysis By Material Type, Function, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，用於醫療植入和組織工程的生物材料的全球市場規模將達到 2,297 億美元，並在預測期內以 13.5% 的複合年成長率成長，到 2034 年達到 6,326 億美元。

用於醫療植入和組織工程的生物材料是指專為在人體內安全發揮作用而設計的特殊材料，同時也能促進組織修復、替代和再生。主要材料類型包括金屬、陶瓷、聚合物、複合材料和生物活性材料，這些材料應用於植入、組織支架、假體和再生醫學領域。材料工程、表面處理和生物製造技術的創新正在不斷提高材料的耐久性、生物相容性、可控分解性和組織整合性。個人化醫療和再生醫學的日益普及正在推動生物材料技術在先進醫療應用中的持續創新。

根據世界衛生組織（WHO）的數據，全球約有 17.1 億人患有肌肉骨骼疾病，因此對整形外科植入、組織修復、關節重建和再生技術產生了顯著的臨床需求。

醫療植入需求不斷成長

整形外科疾病、牙科疾病、心血管疾病和慢性疾病病例的不斷增加，推動了醫療植入對生物材料的需求。老年人口的成長也促進了關節重建、牙科植體、固定系統和心血管器械的應用。具有生物相容性、機械強度、耐腐蝕性和耐久性的材料對於植入的成功和長期療效至關重要。生物材料配方和表面改質技術的進步也提高了植入的安全性、耐久性、組織相容性和功能整合性，促進了其在各種醫療應用中的廣泛應用。

高昂的研發和製造成本

由於需要複雜的研發流程、專用製造設備、嚴格的測試以及可控的生產設施，先進生物材料的研發往往需要大量投資。用於植入和組織工程的產品必須具備安全性、生物相容性、機械強度、分解性能和可靠的長期性能。滿足這些要求會延長研發週期並增加製造商的成本。有限的資金和技術資源尤其會影響中小企業和研究機構，為擴大生產規模、實現新材料商業化以及推廣創新生物材料技術的廣泛應用帶來挑戰。

個人化醫療和再生醫學的擴展

人們對個人化和再生醫學的日益關注，為用於植入和組織工程的先進生物材料創造了新的機會。創新材料正被設計用於與生物系統相互作用，並支持可控癒合、組織修復和再生。客製化植入、可生物分解支架和生物活性材料能夠滿足不同醫療應用中的個人化治療需求。生物技術公司、醫療機構和研究機構之間的合作也在推動技術進步。整形外科、牙科、傷口護理和再生醫學等領域的不斷拓展應用，為生物材料創新創造了更廣泛的機會。

植入排斥和生物相容性問題

生物相容性挑戰、發炎反應以及植入排斥的可能性會威脅生物材料在醫療應用中的開發和推廣。即使產品在設計時特別考慮了生物相容性，患者對植入材料的反應也各不相同。不良反應可能導致醫療設備故障、再次手術以及額外的醫療費用。生物材料與人體組織長期相互作用的不確定性也會影響醫護人員與病患的接受度。因此，製造商在研發創新植入和組織工程技術時，可能面臨更嚴格的測試要求和更長的研發週期。

新型冠狀病毒（COVID-19）的影響：

新冠疫情暫時衝擊了組織工程領域的醫療植入和生物材料市場，擇期手術被推遲，醫院資源重新分配，醫療機構優先應對疫情相關疾病。實驗室運作和研究活動的限制延緩了生物材料的研發和臨床研究。生產和分銷網路也受到干擾，影響了原料和組件的採購。疫情進一步凸顯了可靠的供應鏈、靈活的生產能力以及在再生醫學和生物材料技術領域持續創新的重要性。

在預測期內，金屬生物材料領域預計將佔據最大的市場佔有率。

由於金屬生物材料兼具強度高、耐久性強、可靠性高以及廣泛的醫療應用，預計在預測期內，金屬生物材料領域將佔據最大的市場佔有率。鈦、不銹鋼、鈷鉻合金和其他金屬廣泛應用於整形外科和牙科植入、固定系統以及心血管器械。這些材料具有優異的抗機械應力、耐磨性和耐腐蝕性，並且在體內表現可靠。已建立的臨床記錄進一步支持了這些材料在植入手術中的應用。合金開發、表面工程和塗層技術的不斷改進，正在提升材料的生物相容性、生物相互作用以及與周圍組織的整合能力。

在預測期內，生技和製藥公司板塊預計將呈現最高的複合年成長率。

在預測期內，生物技術和製藥公司板塊預計將呈現最高的成長率，這主要得益於再生醫學、先進療法和生物材料技術領域研究的持續深入。產業相關人員正投資於創新支架、材料和植入解決方案，以應對各種具有挑戰性的醫療應用。與學術機構、實驗室和醫療服務提供者的合作正在推動技術開發和商業化。人們對個人化醫療、組織修復、再生醫學和先進藥物輸送系統的日益關注，進一步刺激了對生物材料的需求，並強化了其在生物技術和製藥研發中的作用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其完善的醫療保健系統、植入的廣泛應用以及在生物材料和組織工程領域的活躍研究。強大的醫院、學術機構、生物技術公司和醫療設備製造商網路為技術開發和臨床應用提供了支援。該地區還擁有整形外科植入、生物材料支架和組織工程醫療產品的既定標準。材料特性、植入設計、再生醫學和生物相容性測試的持續創新，進一步增強了區域生態系統，並推動了先進生物材料解決方案的更廣泛應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健體系的改善和先進療法的普及。組織工程和再生醫學領域的研究活動在全部區域不斷擴展，推動了創新生物材料和植入技術的發展。大規模人口不斷成長的醫療保健需求，以及日益增多的臨床研究和技術進步，都促進了生物材料在整形外科、牙科、循環系統和再生醫學手術等領域的應用範圍不斷擴大。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶的興趣，我們將提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球生物材料市場（用於醫療植入和組織工程）：依材料類型分類

  • 天然生物材料
  • 合成聚合物
  • 金屬生物材料
  • 陶瓷生物材料
  • 複合生物材料

第6章 全球生物材料市場（用於醫療植入和組織工程）：依功能分類

  • 用於結構支撐的生物材料
  • 生物活性和生物功能性生物材料
  • 可生物分解和可吸收的生物材料
  • 不可分解的永久性生物材料

第7章 全球生物材料市場（醫療植入與組織工程）：依應用領域分類

  • 整形外科植入
  • 牙科植體
  • 心血管植入
  • 眼科植入
  • 軟組織植入
  • 組織工程支架

第8章 全球生物材料市場（用於醫療植入和組織工程）：按最終用戶分類

  • 醫院和外科中心
  • 牙醫診所
  • 研究機構和實驗室
  • 生物技術和製藥公司

第9章 全球生物材料市場（用於醫療植入和組織工程）：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Koninklijke DSM NV
  • Corbion NV
  • Zimmer Biomet
  • Noble Biomaterials Inc.
  • Evonik Industries AG
  • Covestro AG
  • Celanese Corporation
  • Carpenter Technology Corporation
  • Victrex plc
  • CeramTec GmbH
  • CoorsTek Inc.
  • BASF SE
  • Collagen Matrix, Inc.
  • Regenity Biosciences
  • Organogenesis Inc.
  • Integra LifeSciences
  • Smith+Nephew
  • MiMedx Group Inc.
Product Code: SMRC39876

According to Stratistics MRC, the Global Biomaterials for Medical Implants & Tissue Engineering Market is accounted for $229.7 billion in 2026 and is expected to reach $632.6 billion by 2034 growing at a CAGR of 13.5% during the forecast period. Biomaterials for Medical Implants & Tissue Engineering encompass specialized materials engineered to function safely within the human body while enabling tissue repair, replacement, and regeneration. Key material classes include metals, ceramics, polymers, composites, and bioactive materials used in implants, tissue scaffolds, prosthetic devices, and regenerative medicine. Innovations in material engineering, surface treatments, and biofabrication are enhancing durability, biological compatibility, controlled degradation, and tissue integration. Increasing adoption of personalized healthcare and regenerative therapies is supporting continued innovation in biomaterial technologies for advanced medical applications.

According to the World Health Organization (WHO), approximately 1.71 billion people globally live with musculoskeletal conditions, creating substantial clinical needs related to orthopedic implants, tissue repair, joint replacement, and regenerative technologies.

Market Dynamics:

Driver:

Rising demand for medical implants

Growing cases of orthopedic problems, dental disorders, cardiovascular conditions, and chronic diseases are increasing the requirement for biomaterials in medical implants. The expanding elderly population is contributing to greater utilization of joint replacements, dental implants, fixation systems, and cardiovascular devices. Materials with biocompatibility, mechanical strength, corrosion resistance, and durability are essential for successful implantation and long-term performance. Advances in biomaterial formulations and surface modification technologies are also improving implant safety, longevity, tissue compatibility, and functional integration, encouraging broader adoption across diverse medical treatment applications.

Restraint:

High development and manufacturing costs

Advanced biomaterials often require substantial investment due to sophisticated research processes, specialized manufacturing equipment, rigorous testing, and controlled production facilities. Products designed for implants and tissue engineering must demonstrate safety, biocompatibility, mechanical strength, degradation characteristics, and reliable long-term performance. Meeting these requirements can extend development periods and increase costs for manufacturers. Limited financial and technical resources may particularly affect smaller companies and research institutions, creating challenges in scaling production, commercializing new materials, and expanding the availability of innovative biomaterial technologies.

Opportunity:

Expansion of personalized and regenerative medicine

Growing interest in personalized and regenerative healthcare is opening new opportunities for advanced biomaterials used in implants and tissue engineering. Innovative materials are being designed to interact with biological systems while supporting controlled healing, tissue repair, and regeneration. Customized implants, biodegradable scaffolds, and bioactive materials can address individual therapeutic requirements across multiple medical applications. Collaboration between biotechnology companies, healthcare providers, and research institutions is also supporting technological advancement. Expanding applications in orthopedics, dentistry, wound management, and regenerative therapies are creating broader opportunities for biomaterial innovation.

Threat:

Risk of implant rejection and biocompatibility issues

Biocompatibility challenges, inflammatory reactions, and potential implant rejection can threaten the development and adoption of biomaterials for medical applications. Patient responses to implanted materials can vary, even when products are specifically engineered for biological compatibility. Negative reactions may result in device failure, revision procedures, and additional healthcare expenses. Uncertainty surrounding the long-term interaction between biomaterials and human tissues may also influence acceptance among healthcare professionals and patients. Consequently, manufacturers may face greater testing requirements and longer development processes for innovative implant and tissue-engineering technologies.

Covid-19 Impact:

The COVID-19 pandemic temporarily affected the Biomaterials for Medical Implants & Tissue Engineering Market as elective procedures were postponed, hospital resources were redirected, and healthcare facilities prioritized pandemic-related care. Restrictions on laboratory operations and research activities delayed biomaterial development and clinical studies. Manufacturing and distribution networks also experienced interruptions, affecting raw material and component availability. The pandemic further highlighted the importance of dependable supply chains, flexible manufacturing capabilities, and continued innovation in regenerative medicine and biomaterial technologies.

The metallic biomaterials segment is expected to be the largest during the forecast period

The metallic biomaterials segment is expected to account for the largest market share during the forecast period due to their combination of strength, durability, reliability, and extensive medical application. Titanium, stainless steel, cobalt-chromium alloys, and other metals are commonly incorporated into orthopedic and dental implants, fixation systems, and cardiovascular devices. Their resistance to mechanical stress, wear, and corrosion enables dependable performance within the body. Established clinical experience further supports their use across implant procedures. Ongoing improvements in alloy development, surface engineering, and coating technologies are enhancing biocompatibility, biological interaction, and integration with surrounding tissues.

The biotechnology & pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology & pharmaceutical companies segment is predicted to witness the highest growth rate, driven by expanding research in regenerative medicine, advanced therapies, and biomaterial technologies. Industry participants are investing in innovative scaffolds, materials, and implant solutions designed for challenging healthcare applications. Partnerships with academic institutions, laboratories, and healthcare providers are supporting technological development and commercialization. Rising interest in personalized treatments, tissue repair, regenerative therapies, and sophisticated drug-delivery systems is creating additional demand for biomaterials and strengthening their role in biotechnology and pharmaceutical research and development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by developed healthcare systems, widespread implant utilization, and substantial research activity in biomaterials and tissue engineering. Strong networks involving hospitals, academic institutions, biotechnology companies, and medical device manufacturers support technological development and clinical adoption. The region also maintains established standards for orthopedic implants, biomaterial scaffolds, and tissue-engineered medical products. Continued innovation in material characterization, implant design, regenerative medicine, and biocompatibility testing is strengthening the regional ecosystem and supporting broader use of advanced biomaterial solutions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by improving healthcare systems and increasing adoption of advanced treatments. Research activity in tissue engineering and regenerative medicine is expanding across the region, with greater development of innovative biomaterials and implant technologies. Rising healthcare requirements among large populations, combined with growing clinical research and technological progress, are supporting broader biomaterial applications in orthopedic, dental, cardiovascular, and regenerative medical procedures.

Key players in the market

Some of the key players in Biomaterials for Medical Implants & Tissue Engineering Market include Koninklijke DSM N.V., Corbion N.V., Zimmer Biomet, Noble Biomaterials Inc., Evonik Industries AG, Covestro AG, Celanese Corporation, Carpenter Technology Corporation, Victrex plc, CeramTec GmbH, CoorsTek Inc., BASF SE, Collagen Matrix, Inc., Regenity Biosciences, Organogenesis Inc., Integra LifeSciences, Smith+Nephew and MiMedx Group Inc.

Key Developments:

In November 2025, Covestro AG and Abu Dhabi's XRG have secured the final regulatory green light for their strategic partnership, winning approval from Germany's Federal Ministry for Economic Affairs and Energy. The decision clears the last remaining hurdle under foreign investment rules, setting the stage for the deal to close within days. The partnership-positioned as a transformative move for the global chemicals sector-will see the two companies push aggressively into innovation, circular production, and digital transformation.

In October 2025, BASF SE and ANDRITZ Group have signed a license agreement for the use of BASF's proprietary gas treatment technology, OASE(R) blue, in a carbon capture project planned to be implemented in the city of Aarhus, Denmark. The project aims to capture approximately 435,000 tons of CO2 annually from the flue gases of a waste-to-energy plant for sequestration; the city of Aarhus has set itself the goal of becoming CO2-neutral by 2030.

In March 2025, Evonik has entered into an exclusive agreement with the Cleveland-based Sea-Land Chemical Company for the distribution of its cleaning solutions in the U.S. The agreement builds on a long-standing relationship with the distributor and expands the reach of Evonik's cleaning solutions to the entire U.S. region.

Material Types Covered:

  • Natural Biomaterials
  • Synthetic Polymers
  • Metallic Biomaterials
  • Ceramic Biomaterials
  • Composite Biomaterials

Functions Covered:

  • Structural Support Biomaterials
  • Bioactive & Biofunctional Biomaterials
  • Biodegradable & Resorbable Biomaterials
  • Non-degradable Permanent Biomaterials

Applications Covered:

  • Orthopedic Implants
  • Dental Implants
  • Cardiovascular Implants
  • Ophthalmic Implants
  • Soft Tissue Implants
  • Tissue Engineering Scaffolds

End Users Covered:

  • Hospitals & Surgical Centers
  • Dental Clinics
  • Research Institutes & Laboratories
  • Biotechnology & Pharmaceutical Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Biomaterials for Medical Implants & Tissue Engineering Market, By Material Type

  • 5.1 Natural Biomaterials
  • 5.2 Synthetic Polymers
  • 5.3 Metallic Biomaterials
  • 5.4 Ceramic Biomaterials
  • 5.5 Composite Biomaterials

6 Global Biomaterials for Medical Implants & Tissue Engineering Market, By Function

  • 6.1 Structural Support Biomaterials
  • 6.2 Bioactive & Biofunctional Biomaterials
  • 6.3 Biodegradable & Resorbable Biomaterials
  • 6.4 Non-degradable Permanent Biomaterials

7 Global Biomaterials for Medical Implants & Tissue Engineering Market, By Application

  • 7.1 Orthopedic Implants
  • 7.2 Dental Implants
  • 7.3 Cardiovascular Implants
  • 7.4 Ophthalmic Implants
  • 7.5 Soft Tissue Implants
  • 7.6 Tissue Engineering Scaffolds

8 Global Biomaterials for Medical Implants & Tissue Engineering Market, By End User

  • 8.1 Hospitals & Surgical Centers
  • 8.2 Dental Clinics
  • 8.3 Research Institutes & Laboratories
  • 8.4 Biotechnology & Pharmaceutical Companies

9 Global Biomaterials for Medical Implants & Tissue Engineering Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Koninklijke DSM N.V.
  • 12.2 Corbion N.V.
  • 12.3 Zimmer Biomet
  • 12.4 Noble Biomaterials Inc.
  • 12.5 Evonik Industries AG
  • 12.6 Covestro AG
  • 12.7 Celanese Corporation
  • 12.8 Carpenter Technology Corporation
  • 12.9 Victrex plc
  • 12.10 CeramTec GmbH
  • 12.11 CoorsTek Inc.
  • 12.12 BASF SE
  • 12.13 Collagen Matrix, Inc.
  • 12.14 Regenity Biosciences
  • 12.15 Organogenesis Inc.
  • 12.16 Integra LifeSciences
  • 12.17 Smith+Nephew
  • 12.18 MiMedx Group Inc.

List of Tables

  • Table 1 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Material Type (2023-2034) ($MN)
  • Table 3 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Natural Biomaterials (2023-2034) ($MN)
  • Table 4 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Synthetic Polymers (2023-2034) ($MN)
  • Table 5 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Metallic Biomaterials (2023-2034) ($MN)
  • Table 6 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Ceramic Biomaterials (2023-2034) ($MN)
  • Table 7 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Composite Biomaterials (2023-2034) ($MN)
  • Table 8 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Function (2023-2034) ($MN)
  • Table 9 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Structural Support Biomaterials (2023-2034) ($MN)
  • Table 10 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Bioactive & Biofunctional Biomaterials (2023-2034) ($MN)
  • Table 11 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Biodegradable & Resorbable Biomaterials (2023-2034) ($MN)
  • Table 12 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Non-degradable Permanent Biomaterials (2023-2034) ($MN)
  • Table 13 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Application (2023-2034) ($MN)
  • Table 14 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Orthopedic Implants (2023-2034) ($MN)
  • Table 15 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Dental Implants (2023-2034) ($MN)
  • Table 16 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Cardiovascular Implants (2023-2034) ($MN)
  • Table 17 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Ophthalmic Implants (2023-2034) ($MN)
  • Table 18 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Soft Tissue Implants (2023-2034) ($MN)
  • Table 19 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Tissue Engineering Scaffolds (2023-2034) ($MN)
  • Table 20 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Hospitals & Surgical Centers (2023-2034) ($MN)
  • Table 22 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Dental Clinics (2023-2034) ($MN)
  • Table 23 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Research Institutes & Laboratories (2023-2034) ($MN)
  • Table 24 Global Biomaterials for Medical Implants & Tissue Engineering Market Outlook, By Biotechnology & Pharmaceutical Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.